NEW YORK (GenomeWeb) – Exosome Diagnostics (ExoDx) today announced it has entered into a collaboration with Takeda Pharmaceuticals to develop an exosomal RNA sequencing platform for biomarker discovery.

Under the terms of the agreement, Cambridge, Massachusetts-based ExoDx and Takeda will develop a platform for analyzing gene expression patterns of cancers and other diseases. ExoDx will apply its exosomal RNA isolation technology, RNA sequencing-based biomarker discovery platform, informatics, and signal enhancement technology, among other methods.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
31
Sponsored by
Roche

This webinar highlights the use of single-cell genomics to identify distinct cell types and states associated with enhanced immunity.